EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury

Thomas G. Nührenberg, Nicolas Langwieser, Johannes B K Schwarz, Yonghao Hou, Pamela Frank, Falko Sorge, Susanne Matschurat, Stefan Seidl, Adnan Kastrati, Albert Schömig, Matthias Clauss, Dietlind Zohlnhöfer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Aims: Neointima formation after vascular injury is strongly associated with inflammation. Rapamycin inhibits human neointima formation and reduces expression of the proinflammatory cytokine endothelial-monocyte activating peptide II (EMAP-II) in vitro. Here we investigated the interplay between EMAP-II and rapamycin after vascular injury in vivo. Methods and results: In a mouse model of vascular injury, mice were either not treated, given everolimus, a rapamycin derivate, or subjected to simultaneous challenge with everolimus and EMAP-II. EMAP-II expression was measured in coronary artery smooth muscle cells (CASMC) and monocytic cells in vitro and in patients after percutaneous coronary intervention (PCI). After vascular injury, rapamycin reduced neointima formation and adventitial thickening. Immunohistochemistry revealed reduced EMAP-II protein expression and suppressed recruitment of inflammatory cells. Simultaneous challenge with EMAP-II counteracted these effects of rapamycin. Expression of EMAP-II and its inhibition by rapamycin was confirmed in CASMC and monocytic cells. In patients, EMAP-II upregulation was confined to PCI of distal coronary artery segments and profoundly suppressed by oral rapamycin treatment. Conclusion: These data suggest important yet unrecognized roles of EMAP-II and adventitial inflammation in neointima formation: Through inhibition of EMAP-II, rapamycin reduces the recruitment of inflammatory cells to the adventitia and supports an early and bland healing.

Original languageEnglish
Pages (from-to)580-589
Number of pages10
JournalCardiovascular Research
Volume77
Issue number3
DOIs
StatePublished - Feb 2008

Fingerprint

Vascular System Injuries
Sirolimus
Monocytes
Down-Regulation
Peptides
Neointima
Adventitia
Coronary Vessels
Percutaneous Coronary Intervention
Smooth Muscle Myocytes
Inflammation
Up-Regulation
Immunohistochemistry
Cytokines

Keywords

  • Adventitia
  • Drugs
  • Endothelium
  • Inflammation
  • Restenosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Nührenberg, T. G., Langwieser, N., Schwarz, J. B. K., Hou, Y., Frank, P., Sorge, F., ... Zohlnhöfer, D. (2008). EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. Cardiovascular Research, 77(3), 580-589. https://doi.org/10.1093/cvr/cvm076

EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. / Nührenberg, Thomas G.; Langwieser, Nicolas; Schwarz, Johannes B K; Hou, Yonghao; Frank, Pamela; Sorge, Falko; Matschurat, Susanne; Seidl, Stefan; Kastrati, Adnan; Schömig, Albert; Clauss, Matthias; Zohlnhöfer, Dietlind.

In: Cardiovascular Research, Vol. 77, No. 3, 02.2008, p. 580-589.

Research output: Contribution to journalArticle

Nührenberg, TG, Langwieser, N, Schwarz, JBK, Hou, Y, Frank, P, Sorge, F, Matschurat, S, Seidl, S, Kastrati, A, Schömig, A, Clauss, M & Zohlnhöfer, D 2008, 'EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury', Cardiovascular Research, vol. 77, no. 3, pp. 580-589. https://doi.org/10.1093/cvr/cvm076
Nührenberg TG, Langwieser N, Schwarz JBK, Hou Y, Frank P, Sorge F et al. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. Cardiovascular Research. 2008 Feb;77(3):580-589. https://doi.org/10.1093/cvr/cvm076
Nührenberg, Thomas G. ; Langwieser, Nicolas ; Schwarz, Johannes B K ; Hou, Yonghao ; Frank, Pamela ; Sorge, Falko ; Matschurat, Susanne ; Seidl, Stefan ; Kastrati, Adnan ; Schömig, Albert ; Clauss, Matthias ; Zohlnhöfer, Dietlind. / EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. In: Cardiovascular Research. 2008 ; Vol. 77, No. 3. pp. 580-589.
@article{25c763a3e2bb4806acb5cacf5080f5ef,
title = "EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury",
abstract = "Aims: Neointima formation after vascular injury is strongly associated with inflammation. Rapamycin inhibits human neointima formation and reduces expression of the proinflammatory cytokine endothelial-monocyte activating peptide II (EMAP-II) in vitro. Here we investigated the interplay between EMAP-II and rapamycin after vascular injury in vivo. Methods and results: In a mouse model of vascular injury, mice were either not treated, given everolimus, a rapamycin derivate, or subjected to simultaneous challenge with everolimus and EMAP-II. EMAP-II expression was measured in coronary artery smooth muscle cells (CASMC) and monocytic cells in vitro and in patients after percutaneous coronary intervention (PCI). After vascular injury, rapamycin reduced neointima formation and adventitial thickening. Immunohistochemistry revealed reduced EMAP-II protein expression and suppressed recruitment of inflammatory cells. Simultaneous challenge with EMAP-II counteracted these effects of rapamycin. Expression of EMAP-II and its inhibition by rapamycin was confirmed in CASMC and monocytic cells. In patients, EMAP-II upregulation was confined to PCI of distal coronary artery segments and profoundly suppressed by oral rapamycin treatment. Conclusion: These data suggest important yet unrecognized roles of EMAP-II and adventitial inflammation in neointima formation: Through inhibition of EMAP-II, rapamycin reduces the recruitment of inflammatory cells to the adventitia and supports an early and bland healing.",
keywords = "Adventitia, Drugs, Endothelium, Inflammation, Restenosis",
author = "N{\"u}hrenberg, {Thomas G.} and Nicolas Langwieser and Schwarz, {Johannes B K} and Yonghao Hou and Pamela Frank and Falko Sorge and Susanne Matschurat and Stefan Seidl and Adnan Kastrati and Albert Sch{\"o}mig and Matthias Clauss and Dietlind Zohlnh{\"o}fer",
year = "2008",
month = "2",
doi = "10.1093/cvr/cvm076",
language = "English",
volume = "77",
pages = "580--589",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury

AU - Nührenberg, Thomas G.

AU - Langwieser, Nicolas

AU - Schwarz, Johannes B K

AU - Hou, Yonghao

AU - Frank, Pamela

AU - Sorge, Falko

AU - Matschurat, Susanne

AU - Seidl, Stefan

AU - Kastrati, Adnan

AU - Schömig, Albert

AU - Clauss, Matthias

AU - Zohlnhöfer, Dietlind

PY - 2008/2

Y1 - 2008/2

N2 - Aims: Neointima formation after vascular injury is strongly associated with inflammation. Rapamycin inhibits human neointima formation and reduces expression of the proinflammatory cytokine endothelial-monocyte activating peptide II (EMAP-II) in vitro. Here we investigated the interplay between EMAP-II and rapamycin after vascular injury in vivo. Methods and results: In a mouse model of vascular injury, mice were either not treated, given everolimus, a rapamycin derivate, or subjected to simultaneous challenge with everolimus and EMAP-II. EMAP-II expression was measured in coronary artery smooth muscle cells (CASMC) and monocytic cells in vitro and in patients after percutaneous coronary intervention (PCI). After vascular injury, rapamycin reduced neointima formation and adventitial thickening. Immunohistochemistry revealed reduced EMAP-II protein expression and suppressed recruitment of inflammatory cells. Simultaneous challenge with EMAP-II counteracted these effects of rapamycin. Expression of EMAP-II and its inhibition by rapamycin was confirmed in CASMC and monocytic cells. In patients, EMAP-II upregulation was confined to PCI of distal coronary artery segments and profoundly suppressed by oral rapamycin treatment. Conclusion: These data suggest important yet unrecognized roles of EMAP-II and adventitial inflammation in neointima formation: Through inhibition of EMAP-II, rapamycin reduces the recruitment of inflammatory cells to the adventitia and supports an early and bland healing.

AB - Aims: Neointima formation after vascular injury is strongly associated with inflammation. Rapamycin inhibits human neointima formation and reduces expression of the proinflammatory cytokine endothelial-monocyte activating peptide II (EMAP-II) in vitro. Here we investigated the interplay between EMAP-II and rapamycin after vascular injury in vivo. Methods and results: In a mouse model of vascular injury, mice were either not treated, given everolimus, a rapamycin derivate, or subjected to simultaneous challenge with everolimus and EMAP-II. EMAP-II expression was measured in coronary artery smooth muscle cells (CASMC) and monocytic cells in vitro and in patients after percutaneous coronary intervention (PCI). After vascular injury, rapamycin reduced neointima formation and adventitial thickening. Immunohistochemistry revealed reduced EMAP-II protein expression and suppressed recruitment of inflammatory cells. Simultaneous challenge with EMAP-II counteracted these effects of rapamycin. Expression of EMAP-II and its inhibition by rapamycin was confirmed in CASMC and monocytic cells. In patients, EMAP-II upregulation was confined to PCI of distal coronary artery segments and profoundly suppressed by oral rapamycin treatment. Conclusion: These data suggest important yet unrecognized roles of EMAP-II and adventitial inflammation in neointima formation: Through inhibition of EMAP-II, rapamycin reduces the recruitment of inflammatory cells to the adventitia and supports an early and bland healing.

KW - Adventitia

KW - Drugs

KW - Endothelium

KW - Inflammation

KW - Restenosis

UR - http://www.scopus.com/inward/record.url?scp=38849088686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849088686&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvm076

DO - 10.1093/cvr/cvm076

M3 - Article

VL - 77

SP - 580

EP - 589

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 3

ER -